帕洛克索纳斯I活性及其与营养的关系在肌缩侧面硬化症中
Belén Proaño1, María Benlloch2, Sandra Sancho-Castillo3
1Doctoral School, Catholic University of Valencia, 46001 Valencia, Spain.
Antioxidants (Basel, Switzerland)
|August 29, 2024
概括
氧酶1 (PON1) 活性直接和通过呼吸功能对肌缩性侧面硬化症 (ALS) 患者的功能产生积极影响. 在这项研究中,其与营养的联系很弱.
科学领域:
- 神经学 神经学
- 生物化学 生物化学
- 氧化压力研究研究 氧化压力研究
背景情况:
- 肌缩性侧面硬化症 (ALS) 涉及运动神经元退化和氧化应激.
- 氧酶1 (PON1) 是一种抗氧化酶,可能会影响ALS的进展.
- 了解PON1的作用对于管理ALS患者的功能至关重要.
研究的目的:
- 开发一种对PON1活动对ALS患者功能影响的预测模型.
- 为了研究PON1活性,营养和ALS的临床标志物之间的关系.
- 通过呼吸和心血管参数来探索PON1对功能间接的影响.
主要方法:
- 70名ALS患者的观测横截面研究.
- 评估PON1活动,脂质概况,功能能力,呼吸功能和心率变化.
- 结构方程建模和营养摄入量分析.
主要成果:
- 直接和通过呼吸能力,PON1活动和LDL积极预测功能.
- 心率变化独立预测的功能.
- 高脂水平与功能没有显著的关联.
- 在PON1活性和营养摄入量之间观察到微弱的相关性 (对单不和脂肪,维生素D呈阳性;对碳水化合物,蛋白质呈阴性).
结论:
- PON1活动对ALS患者的功能很重要,直接和通过呼吸能力影响它.
- 在这个队列中,PON1活动和营养摄入量之间的关联并不强大.
- 进一步的研究可能会阐明PON1在ALS病原和治疗中的复杂作用.
相关概念视频
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
Parkinson's Disease: Overview
499
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
499
Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K
Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239


